Amgen's Aimovig won its first-in-class migraine nod. Will payers step up to the $6,900 price?

Amgen’s Aimovig won its first-in-class migraine nod. Will payers step up to the $6,900 price?

Amgen and Novartis inaugurated a much-anticipated new class of migraine medication Wednesday with FDA approval for Aimovig, an injectable med laden with blockbuster hopes. But Aimovig has a number of extra hurdles to clear earlier than it can attain these lofty objectives.

The companions want to win over payers which have already warned how expensive this new sort of med—which targets the calcitonin gene-related peptide pathway—might be to the healthcare system, they usually’ve began by setting the worth at $6,900 per 12 months, decrease than the $eight,000 to $10,000 payers had warned in opposition to.

With a rival drug from Eli Lilly solely months behind, Amgen and Novartis have a restricted period of time to make the most of their first-mover benefit. Already, an Express Scripts consultant stated the firm can have a previous authorization program in place to handle entry to Aimovig.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world the place large concepts come alongside every day. Our subscribers depend on FiercePharma as their must-read supply for the newest information, evaluation and knowledge on medication and the firms that make them. Sign up at present to get pharma information and updates delivered to your inbox and browse on the go.

The approval is arguably extra vital for Amgen, which is bracing for new biosimilar competitors for some key merchandise, together with the anemia drug Neupogen. But Novartis has its personal monetary challenges, together with generic competitors for its big-selling leukemia drug Gleevec, and with a political scandal raging, it can use this dose of fine information.

With Wednesday’s nod, the race is on. Amgen had the likelihood to set preliminary pricing in the class, VP of Development Rob Lenz stated forward of the approval, and now it may possibly work to seize what he referred to as “pent-up demand” for higher migraine meds. “There’s a lot of buzz in the field,” he stated of affected person and physician pleasure for the drug. “This is the first preventative therapy ever designed specifically for migraine.” 

As Lenz identified, older migraine medication have been repurposed from different makes use of. That lack of purpose-built remedies is one purpose why the cGRP class is so crowded, with different entrants anticipated from Teva and Allergan in addition to Lilly. But Teva’s drug, which could have been accredited subsequent month, will likely be delayed by manufacturing issues, that firm stated in February, giving Amgen and Novartis a bit extra runway for his or her launch than beforehand anticipated. Allergan’s, anticipated to be the first oral CGRP drug, is farther behind, with a possible FDA submitting subsequent 12 months.

RELATED: The top 15 drug patent expirations of 2018NeulastaEpogenSensipar

Patients will admire a tolerability profile that is “similar to a sugar pill” and efficacy that might be seen inside days, Lenz stated. The once-monthly self-injection permits sufferers “built-in compliance” as a result of they do not have to bear in mind to take a capsule daily, he stated. Lilly’s injection can also be month-to-month, whereas Teva’s has been examined with month-to-month and quarterly schedules.

Payers might be a harder crowd, however Amgen might give you the chance to apply some classes it discovered whereas launching Repatha, a PCSK9 ldl cholesterol drug with blockbuster ambitions. It rapidly bumped into payer resistance, although, and uptake nonetheless is not as robust as anticipated.

In an effort to win favorable protection, Amgen—and its rivals, Regeneron and Sanofi—ran giant outcomes trials hoping to present the medication might ship cardiovascular advantages. But even with knowledge displaying the medication might scale back CV dangers, the PCSK9 drugmakers have discounted their meds by 40% or extra to acquire protection. The dynamics have led to gross sales far under preliminary projections.

RELATED: What’s your Aimovig rollout plan, Amgen? Growth-hungry investors want to know 

With that in thoughts, analysts have raised questions on uptake for the new migraine medication. In a notice this week, Wells Fargo analyst David Maris stated it stays to be seen whether or not CGRP meds “will be the next PCSK9-like category–a major advance that must be priced low in order to get access.” 

Aimovig’s approval intently follows a Praluent low cost deal Maris sees as a possible harbinger of hassle for the new migraine medication. For an unique spot on the PBM’s formulary—and entry to hundreds of thousands of sufferers it covers—Regeneron and Sanofi provided up large worth cuts. The deal “does not bode well for the anti-CGRP drug class,” Maris wrote this week. At the time of the deal, Bernstein analyst Ronny Gal referred to as it a “capitulation,” as a result of it is tacit admission that the class won’t ever change into a significant industrial success.

“When classes go exclusive, payers win,” Gal stated in a video discussing the deal. 

Payers have been eyeing CGRP medication already. In a latest Reuters interview, Express Scripts chief medical officer Steve Miller urged Amgen keep away from the typical method of setting a excessive listing worth and providing giant rebates and reductions. The firm might attempting narrowing the “gross-to-net” hole as a substitute, he urged.

In a press release Thursday, an Express Scripts spokesperson stated Amgen is “being responsible” with its Aimovig pricing. While citing “serious unmet need” for migraine victims, she stated not all sufferers will want Aimovig. Express Scripts believes the drug is suitable for sufferers who’ve failed on a earlier preventative remedy.

With that thought-about, the firm will “have a prior authorization program in place to help payers get the most value for the money they spend,” she added.

Amgen and Novartis are co-marketing Aimovig underneath a partnership first struck in 2015 and expanded final April. Under the newest settlement, the firms will co-commercialize the drug in the U.S. Amgen will e book U.S. gross sales and pay Novartis royalties on them, whereas Novartis will e book ex-U.S. gross sales and pay Amgen royalties for revenues elsewhere. Amgen has unique rights in Japan, and Novartis has unique rights in Canada.

RELATED: Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar

Thursday’s approval comes forward of some critical competitors for different Amgen meds. This week, Pfizer won approval for its biosimilar of anemia blockbuster Epogen, with plans to launch this 12 months. Amgen might additionally face new competitors this 12 months on Neulasta and on calcium Sensipar.  

Together, these medication generate billions of gross sales, and Amgen is aware of Aimovig will likely be a key issue for progress as these medication fall off the patent cliff. Analysts predict Aimovig can generate $1.2 billion in gross sales by 2022.

Source link